FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia

글 내용 전체보기

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

글 내용 전체보기

Morgan Stanley Global Healthcare Conference Update: Lilly, Amgen and Biogen

글 내용 전체보기

Medtech Company Endotronix Snags $45 Million in Series D Funding

글 내용 전체보기

September 14 Research Roundup: Brain in a Dish, Pathway Map for Diabetes, and “Finding Nemo’s” Genome

글 내용 전체보기

Patient groups rebuke CVS on ICER, saying cost-effectiveness reviews discriminate

글 내용 전체보기

In a blood cancer win, AstraZeneca nabs FDA nod for rare leukemia drug Lumoxiti

글 내용 전체보기

Sun wins approval of glaucoma drug and its once-troubled Halol plant to produce it

글 내용 전체보기

With EU salivating after Humira biosims, analysts start questioning AbbVie’s optimism

글 내용 전체보기

Takeda eyes Shire product sales of up to $5B to pay down debt: Bloomberg

글 내용 전체보기

Strange bedfellows: Allergy paid search pits diverse brands against each other

글 내용 전체보기

FiercePharmaAsia—Takeda’s internal discord and U.S. HQ move; Sanofi reorg and more

글 내용 전체보기

J&J execs say new launches and label expansions will fuel ‘above-market’ growth through 2021

글 내용 전체보기

Allergan defuses Botox threat with $195M Bonti buy

글 내용 전체보기

FDA sets back review date of Acorda’s levodopa inhaler for Parkinson’s disease

글 내용 전체보기

5 months after launch, Allogene guns for $100M IPO

글 내용 전체보기

Supernus adds epilepsy candidate with $185M Biscayne buy

글 내용 전체보기

Chutes & Ladders—Ex-Gilead CMO Andrew Cheng to lead Akero

글 내용 전체보기

Bone Therapeutics’ cell therapy hits goal in phase 1/2a, but manufacturing changes slow progress

글 내용 전체보기

Catalent clears up FDA 483 concerns at Indiana plant

글 내용 전체보기

Science learns from its mistakes too

글 내용 전체보기